Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab in Recurrent or Relapsed Solid Tumors
NCT03320330Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pepinemab in Solid neoplasm, osteosarcoma (OS), sponsored by Children's Oncology Group. Started Jan 2018; status: completed.
02
Drugs
pepinemab
03
Conditions
Solid neoplasmosteosarcoma (OS)
Beyond the preview
Go deeper on NCT03320330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320330.